Ferlay J, Bray F, Pisani P, et al. Globocan/Eucan 2000: Cancer incidence, mortality and prevalence worldwide. Available from URL:
http://www-dep.iare.fr/dataava/infodata.htm
[Accessed 2003 Jan 31]
Eucan cancer incidence, mortality and prevalence in the European Union. Available from URL:
http://www-dep.iare.fr/eucan/eucan.htm
[Accessed 2003 Feb 19]
American Cancer Society (ACS). Cancer facts and figures 2002. Available from URL:
[Accessed 2003 Feb 7]
Greenlee RT, Hill-Harmon MB, Thun M. ACS cancer statistics 2001. CA Cancer J Clin 2001; 51: 15–36
Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999; 340: 77–84
Fisher B, Constantino JP, Wickerman DL, et al. Tamoxifen for prevention of breast cancer. Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Just 1998; 16:1371–88
Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from MORE randomized trial. 10-Multiple Outcomes of Raloxifene Evaluation. JAMA 1999; 281(23):2189–97
The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999; 281 (23): 2189–97
Henderson MM, Kushi LH, Thompson DJ, et al. Feasibility of a randomized trial of a low-fat diet for the prevention of breast cancer: dietary compliance in the Women’s Health Trial Vanguard Study. Prev Med 1990; 19 (2): 115–33
USPSTF. Chemoprevention of breast cancer: recommendations and rationale. Ann Intern Med 2002 Jul 2; 137 (1): 56–69
ASCO update on breast cancer chemoprevention. Inpharma 2002 Feb 16; 1325: 1–14
Goss PE, Strasser K. Chemoprevention with aromarase inhibitors-trial strategies. J Steroid Biochem Mol Biol 2001 Dec; 79 (1–5): 143–9
Veronesi U, Saccozzi R, Del Vecchio M, et al. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med 1981; 305: 6–11
Sarrazin D, Le MG, Fontaine MF, et al. Conservative treatment versus mastectomy in TI or small T2 breast cancer: a randomized trial. In: Hams JR, Hellman S, Silver W, editors. Conservative management of breast cancer: new surgical and miotherapeutic techniques. Philadelphia (PA): J.B. Lipencott, 1983:101–11
Fisher B, Redmond C, Fisher ER, et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985; 312: 674–81
van Dongen E. Breast conserving therapy in operable breast cancer. EORTC Working Conference on Breast Cancer; 1987 Jul 1-3; London
Lichter AS, Lippman ME, Danforth DN, et al. Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast: a randomized trial at the National Cancer Institute. J Clin Oncol 1992; 10: 976–83
Perez EA, Hortobagyi GN. Ongoing and planned adjuvant trials with trastuzumab. Semin Oncol 2000 Dec; 27 (6 Suppl. 1): 26–32
Lonning PE. Aromatase inhibitors and inactivators in breast cancer. BMJ 2001 Oct 20; 323 (7318): 880–1
Buzdar AU. A summary of second-line randomized studies of aromarase inhibitors J Steroid Bio & Mol Biol 2001; 79 (201): 109–14
Fisher B, Costantino J, Redmond C. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-sensitive tumours. N Engl J Med 1989; 320: 478–84
Twombly R. Upstaging tamoxifen? New classes of drugs emerging for breast cancer. J Natl Cancer Inst 2002 Apr 3; 94 (7): 474–5
Howell A, Howell SJ, Clarke R, et al. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithm? J Steroid Biochem Mol Biol 2001; 79 (1–5): 227–37
Lonning PE. Aromarase inhibitors and inactivators for breast cancer therapy. Drugs Aging 2002; 19 (4): 277–98
Ragaz J. Adjuvant trials of aromarase inhibitors: determining the future landscape of adjuvant endocrine therapy. J Steroid Biochem Biol 2001 Dec; 79 (1–5): 133–41
Gelber RD, Cole BF, Gelber S, et al. The Q-TWiST method: quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia (PA): Lippincott-Raven Publishers, 1996
Radice D, Redaelli A. Non-parametric Q-TWiST analysis of intensive CEF versus standard CMF as adjuvant therapy for breast carcinoma in pre-menopausal patients with histologically involved axillary nodes. Qual Life Res 2000; 9 (9): 1065–6
Efficace F, Bottomley A, Collins GS. Quality of life in breast cancer: measurement issues in cancer clinical trials. Expert Rev Pharmacoeconomics Outcomes Res 2002; 2 (1): 57–65
Hurny C, Bernhard J, Coates AS, et al. Impact of adjuvant therapy on quality of life in women with node positive operable breast cancer. Lancet 1996; 347: 1279–84
Selby PJ, Campbell JE, Chapman JA, et al. Measurement of the quality of life in patients with breast cancer. Rev Endocr Related Cancer 1984; 14: 245–7
Priestman TJ, Baum M. Evaluation of quality in patients receiving treatment for advanced breast cancer. Lancet 1976; 24: 899–900
Priestman TJ. Quality of life after cytotoxic chemotherapy: discussion paper. J R Soc Med 1984; 77: 492–5
Padilla GV, Preasant C, Grant MM, et al. Quality of life index for patients with cancer. Res Nuts Health 1983; 6: 117–26
Stiggelbout AM, Jansen SIT, De Haes JCJM, et al. Adjuvant chemotherapy in breast cancer: do ratings of side effects explain differences in preferences? [poster]. ASCO Conference; 1999 May 15–18; Atlanta (GA)
Bernhard J, Castiglione-Gertsch M, Schmitz SF, et al. Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Eur J Cancer 1999; 35: 913–20
Hurny C, Berhard J, Gelber RD, et al. Quality of life measures for patients receiving adjuvant therapy for breast cancer: an international trial. Eur J Cancer 1992; 18 (1): 118–24
Coates A, Gebski V, Signorini D, et al. Prognostic value of quality of life scores during chemotherapy for advanced breast cancer. J Clin Oncol 1992; 10 (12): 1833–8
Shimozuma K, Sonoo H, Ichihra K, et al. The prognostic value of quality of life scores: preliminary results of an analysis of patients with breast cancer. Surg Today 2000; 30: 255–61
Macquart-Moulin G, Viens P, Genre D, et al. Concomitant chemoradiotherapy for patients with nonmetastatic breast carcinoma: side effects, quality of life and daily organization. Cancer 1999; 85: 2190–9
Wyatt G, Kurtz ME, Liken M. Breast cancer survivors: an exploration of quality of life issues. Cancer Nuts 1993; 16: 440–8
Mor V, Malin M, Allen S. Age differences in the psychosocial problems encountered by breast cancer patients. J Natl Cancer Inst Monogr 1994; 16: 191–7
Edlund B, Sneed NV. Emotional responses to the diagnosis of cancer: age-related comparisons. Oncol Nuts Forum 1989; 16: 691–7
Schagen SB, Booger W, Muller MJ, et al. Cognitive impairment as late effect of adjuvant chemotherapy for breast cancer. O-N-E 2000; 1 (9): 48–51
McPherson K, Steel CM, Dixon JM. ABC of breast diseases. Breast cancer: epidemiology, risk factors and genetics. BMJ 1994; 309: 1003–6
Brown ML, Hodgson TA, Rice DP. Economic impact of cancer in the United States. NCI 1994; 13: 255–66
Thom TJ. Economic costs of neoplasms, arteriosclerosis, and diabetes in the United States. In Vivo 1996; 10: 255–60
Brown HL, Fintor L. The economic burden of cancer. NCI 1990; 5: 69–81
White E, Urban N, Taylor V. Mammography utilization, public health impact on cost-effectiveness in the United States. Annu Rev Public Health 1993; 14: 605–33
Shapiro S, Venet W, Strax P, et al. Ten-to-fourteen year effect of screening on breast cancer mortality. J Natl Cancer Inst 1982; 326: 653–7
Greenberg ER, Chute CG, Stukel T, et al. Social and economic factors in the choice of lung cancer treatment: a population based study in two states. N Engl J Med 1988; 313: 612–7
Lazovich DA, White E, Thomas DB, et al. Underutilization of breast-conserving surgery and radiation therapy among women with stage I or II breast cancer. JAMA 1991; 266: 3433–8
Newcomp PA, Carbone PP. Cancer treatment and age: patient perspectives. J Natl Cancer Inst 1993; 85: 1580–4
Taplin SH, Barlow W, Urban N, et al. Stage, age, comorbidity and direct costs of colon, prostate and breast cancer care. J Natl Cancer Inst 1995; 87 (6): 417–26
Baker MS, Kessler LG, Urban N, et al. Estimating the treatment costs of breast and lung cancer. Med Care 1991; 29: 40–9
Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992; 45: 197–203
Will BP, Le Petit C, Berthelot JM, et al. Diagnostic and therapeutic approaches for non metastatic breast cancer in Canada, and their associated costs. Br J Cancer 1999; 79 (10): 1428–36
Will BP, Berthelot JM, Le Petit C, et al. Estimates of the lifetime costs of breast cancer treatment in Canada. Eur J Cancer 2000; 36: 724–35
Riley GF, Potosky AL, Lubitz JD, et al. Medicare payments from diagnosis to death for elderly patients by stage at diagnosis. Med Care 1995; 33: 828–41
Wolstenhome JL, Smith SJ, Whynes DK. The cost of treating breast cancer in the United Kingdom: implications for screening. Int J Technol Assess Health Care 1998; 14: 277–89
Berkowitz N, Gupta S, Silberman G. Estimates of the lifetime direct costs of treatment for metastatic breast cancer. Value Health 2000; 3 (1): 23–30
Clark GM. Prognostic and predictive factors. In: Jarris JR, Lippman ME, Morrow M, et al. (editors). Diseases of the breast. Philadelphia (PA): Lippincott-Raven Publishers, 1996: 461–85
McPherson K, Steel CM, Dixon JM. ABC of breast diseases. Breast cancer — epidemiology, risk factors and genetics. BMJ 1994; 309: 1003–6